MRUS - Merus NV Stock Price, Fair Value and News

$41.85-0.24 (-0.57%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MRUS Price Action

Last 7 days

-2.3%

Last 30 days

-2.5%

Last 90 days

-15.7%

Trailing 12 Months

58.5%

MRUS RSI Chart

MRUS Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-11.72

Price/Sales (Trailing)

79.74

EV/EBITDA

-10.36

Price/Free Cashflow

-18.23

MRUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRUS Fundamentals

MRUS Revenue

Revenue (TTM)

35.9M

Rev. Growth (Yr)

6.7%

Rev. Growth (Qtr)

60.56%

MRUS Earnings

Earnings (TTM)

-244.6M

Earnings Growth (Yr)

-334.14%

Earnings Growth (Qtr)

-99.64%

MRUS Profitability

EBT Margin

-659.93%

Return on Equity

-34.77%

Return on Assets

-28.95%

Free Cashflow Yield

-5.48%

MRUS Investor Care

Shares Dilution (1Y)

26.13%

Diluted EPS (TTM)

-3.93

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	38.3M	35.2M	35.9M	0
2023	43.4M	41.2M	45.7M	43.9M
2022	52.4M	52.7M	45.6M	41.6M
2021	32.0M	38.3M	43.4M	49.1M
2020	28.6M	28.3M	28.7M	29.9M
2019	36.6M	34.8M	32.9M	31.1M
2018	26.0M	30.1M	34.3M	38.4M
2017	7.4M	12.2M	17.1M	21.9M
2016	0	0	0	2.5M
2015	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

CEO	Dr. Sven Ante Lundberg M.D.
WEBSITE	merus.nl
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	164

Merus NV Frequently Asked Questions

What is the ticker symbol for Merus NV? What does MRUS stand for in stocks?

MRUS is the stock ticker symbol of Merus NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merus NV (MRUS)?

As of Fri Dec 20 2024, market cap of Merus NV is 2.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRUS stock?

You can check MRUS's fair value in chart for subscribers.

Is Merus NV a good stock to buy?

The fair value guage provides a quick view whether MRUS is over valued or under valued. Whether Merus NV is cheap or expensive depends on the assumptions which impact Merus NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRUS.

What is Merus NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, MRUS's PE ratio (Price to Earnings) is -11.72 and Price to Sales (PS) ratio is 79.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRUS PE ratio will change depending on the future growth rate expectations of investors.